These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Botulinum toxin type A for facial rejuvenation. United States and United Kingdom perspectives.
    Author: Lowe NJ.
    Journal: Dermatol Surg; 1998 Nov; 24(11):1216-8. PubMed ID: 9834741.
    Abstract:
    BACKGROUND: Botulinum A toxin has been well documented as a successful treatment for hyperfunctional upper facial expression lines. Currently, there are two commercial sources for botulinum toxin--Botox and Dysport. Only Botox is currently available in the United States; however, both Botox and Dysport are available in a number of European and other countries. OBJECTIVES: There are several differences between these two sources of botulinum toxin, including different potency of their dosage units. This article will review the uses of these two sources of botulinum toxin and discuss the dilution and dosing of botulinum toxin for facial expression lines. RESULTS: One unit of Botox is approximately equivalent in potency to 4 U of Dysport. CONCLUSIONS: Both commercial types of botulinum toxin can be used interchangeably with appropriate dosage selection.
    [Abstract] [Full Text] [Related] [New Search]